1. Knowledge l Action l Impact
Clinical Need, Economic & Market Analysis
Biomarker Discovery
Clinical
Utility
Analytical
Development
Biomarker Replication & Technical Validation
Use
Clinical Validation
Biomarker Candidates have been identified
Performance
Characteristics
Confirmed
Benefit
Biomarker Development
Assay Development
Clinical Development
Biomarkers that diagnose prostate cancer accurately
Biomarkers that inform if a given prostate cancer is likely to metastasize
Biomarker Candidates have been selected:
Cancer Microparticles for diagnosis and metastasis
Metabolomic signatures
Genetic signatures
Migration/progression biomarkers
Retrospective validation cohorts have been identified
Prospective validation cohort is being enrolled and estimated 9,000 patients will be recruited in the next 5 years

2. Research Themes at APCaRI
“APCaRI is developing and validating new diagnostic and prognostic biomarkers for management of prostate cancer. Being able to distinguish patients with aggressive disease will allow for rapid, intense therapy to avoid metastasis to occur.”
Research Themes at APCaRI
Biomarkers for diagnosis of prostate cancer
A team-based biomarker validation pipeline: Our team focuses on technology platforms that can interrogate events downstream from the primary tumour in the blood, urine and semen including Cancer microparticles, Metabolomics and Imaging.
Biomarkers for metastasis
Predicting metastasis using a unique antibodies: Prostate Cancer Microparticles, Migration Switch platform, Metabolomic Profiling, Proteomic Platforms
Gene - based projects
A 10 gene signature of aggressive prostate cancer: Members of our group have recently identified the primary differentially-expressed genes identifying patients at highest risk of cancer mortality through Gene Signatures and Genomic Platforms
Database and Tools for Evidence-Based Healthcare
Information Sources to Improve Outcomes: Alberta Prostate Cancer Registry and tools to support Real-Time Evidence-Based Medicine